Anticancer Therapies – News and Features

Two bacterial strains may be linked to higher rates of colon cancer in some countries. This may provide a target for the development of measures such as vaccines to cut rates of colon cancer.

A groundbreaking new database could lead to vast improvements in precision oncology by documenting sex-based differences in cancer treatment efficacy, biomarkers, risk factors, and microbial influences across 71 cancer types.

This article explores some of the challenges in developing cell lines for therapeutics, such as cell line stability, and how they are being addressed.

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, researchers showed.

Researchers used glioblastoma-derived organoids to predict patient responses to CAR T cell therapy with remarkable accuracy. These organoids mirrored the tumor’s reaction to treatment in real time, offering insights into efficacy and neurotoxicity.

A UT Southwestern trial found selinexor, an FDA-approved drug, effective in KRAS-mutated non-small cell lung cancer (NSCLC). Combined with chemotherapy, it achieved tumor control in 80% of cases.

A clinical trial combining chemotherapy with immunotherapy blinatumomab reduced relapse risk in B-ALL by 61%. The study marked a milestone in pediatric leukemia care, with survival rates rising to 97.5%.

Scientists discovered a key protein, SLIRP, vital for muscle energy production. Exercise was found to bypass genetic defects affecting mitochondrial function. The findings could lead to therapies mimicking exercise’s benefits.

UCSF researchers have engineered T cells to temper overactive immune responses by targeting inflammation and soothing immune activity. The technology successfully protected transplanted pancreatic islet cells in a type 1 diabetes model.

The therapy molecule AZD7648 can promote precise DNA repair during CRISPR gene editing, but creates massive genetic changes elsewhere.